Co-Diagnostics, Inc. Hosts Investor Presentation on Co-Dx PCR Platform

What Happened

• Co-Diagnostics, Inc. (CODX) filed a Form 8-K (Regulation FD disclosure) to announce that it will host an investor and analyst presentation on September 16, 2026.
• The presentation will address the company’s collaboration with ReadyGo Diagnostics Ltd., updates on the Co-Dx PCR platform and related development activities, manufacturing initiatives, and the company’s operations in India.
• Presentation materials are furnished as Exhibit 99.1 to the Form 8-K and are incorporated by reference.

Key Details

• Date of presentation: September 16, 2026.
• Topics disclosed: collaboration with ReadyGo Diagnostics Ltd.; Co-Dx PCR platform development; manufacturing initiatives; operations in India.
• Filing type: Form 8-K, Item 7.01 (Regulation FD Disclosure); Exhibit 99.1 (Investor and Analyst Presentation).

Why It Matters

• The presentation provides investors a direct update on product development, partnerships and manufacturing plans that could affect future commercialization and supply execution for CODX’s PCR products.
• Because the disclosure was filed under Regulation FD, the company is sharing material information broadly and in compliance with fair disclosure rules; investors can review the furnished presentation (Exhibit 99.1) for specifics.